SELLAS Life Sciences Group, Inc. (SLS): Price and Financial Metrics


SELLAS Life Sciences Group, Inc. (SLS): $2.55

0.03 (+1.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SLS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SLS POWR Grades

  • Growth is the dimension where SLS ranks best; there it ranks ahead of 69.17% of US stocks.
  • SLS's strongest trending metric is Value; it's been moving down over the last 177 days.
  • SLS's current lowest rank is in the Momentum metric (where it is better than 4.49% of US stocks).

SLS Stock Summary

  • The ratio of debt to operating expenses for SELLAS LIFE SCIENCES GROUP INC is higher than it is for about only 7.26% of US stocks.
  • SLS's price/sales ratio is 51.88; that's higher than the P/S ratio of 96.33% of US stocks.
  • As for revenue growth, note that SLS's revenue has grown -89.47% over the past 12 months; that beats the revenue growth of merely 1.38% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SELLAS LIFE SCIENCES GROUP INC are ABEO, APVO, RBBN, SPOK, and SNCR.
  • Visit SLS's SEC page to see the company's official filings. To visit the company's web site, go to www.sellaslifesciences.com.

SLS Valuation Summary

  • In comparison to the median Healthcare stock, SLS's EV/EBIT ratio is 110.34% lower, now standing at -0.9.
  • Over the past 179 months, SLS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for SLS.

Stock Date P/S P/B P/E EV/EBIT
SLS 2022-12-02 55.0 4.4 -1.4 -0.9
SLS 2022-12-01 53.5 4.2 -1.4 -0.8
SLS 2022-11-30 49.2 3.9 -1.3 -0.7
SLS 2022-11-29 48.0 3.8 -1.2 -0.7
SLS 2022-11-28 47.4 3.8 -1.2 -0.7
SLS 2022-11-25 49.0 3.9 -1.3 -0.7

SLS Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 109.64%.
  • Its 3 year net income to common stockholders growth rate is now at 3.38%.
  • Its year over year net income to common stockholders growth rate is now at -133.34%.
Over the past 52 months, SLS's revenue has gone up $1,000,000.

The table below shows SLS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1 -23.633 -38.778
2022-06-30 1 -23.765 -38.841
2022-03-31 2.9 -22.902 -35.04
2021-12-31 7.6 -26.021 -20.699
2021-09-30 9.5 -17.621 -17.817
2021-06-30 9.5 -15.372 -15.205

SLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SLS has a Quality Grade of D, ranking ahead of 22.65% of graded US stocks.
  • SLS's asset turnover comes in at 0.255 -- ranking 173rd of 680 Pharmaceutical Products stocks.
  • ZSAN, MNOV, and OVID are the stocks whose asset turnover ratios are most correlated with SLS.

The table below shows SLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.255 0.979 -3.728
2021-03-31 0.254 0.987 -4.352
2020-12-31 0.079 1.000 -5.135
2020-09-30 0.000 NA -4.595
2020-06-30 0.000 NA -4.552
2020-03-31 0.000 NA -4.415

SLS Price Target

For more insight on analysts targets of SLS, see our SLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.50 Average Broker Recommendation 1.5 (Moderate Buy)

SLS Stock Price Chart Interactive Chart >

Price chart for SLS

SLS Price/Volume Stats

Current price $2.55 52-week high $7.40
Prev. close $2.52 52-week low $1.77
Day low $2.51 Volume 2,548
Day high $2.55 Avg. volume 235,744
50-day MA $2.92 Dividend yield N/A
200-day MA $3.35 Market Cap 52.41M

SELLAS Life Sciences Group, Inc. (SLS) Company Bio


SELLAS Life Sciences, Ltd. is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.


SLS Latest News Stream


Event/Time News Detail
Loading, please wait...

SLS Latest Social Stream


Loading social stream, please wait...

View Full SLS Social Stream

Latest SLS News From Around the Web

Below are the latest news stories about SELLAS LIFE SCIENCES GROUP INC that investors may wish to consider to help them evaluate SLS as an investment opportunity.

SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model

GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib Results support designating small cell lung cancer as first indication in planned solid cancer basket trial for GFH009 NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of ca

Yahoo | December 1, 2022

SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit

NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present at the JMP Securities Hematology and Oncology Summit, a virtual investor conference being held from December 6-7, 2022. Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS

Yahoo | November 30, 2022

SELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)

SELLAS Life Sciences Group ( NASDAQ:SLS ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.02m (flat on...

Yahoo | November 16, 2022

SELLAS Life Sciences Group (SLS) Gets a Buy from Maxim Group

Maxim Group analyst Jason McCarthy reiterated a Buy rating on SELLAS Life Sciences Group (SLS - Research Report) yesterday and set a price target of $12.00. The company's shares opened today at $2.50.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, SELLAS Life Sciences Group, and Daré Bioscience. According to TipRanks, McCarthy has an average return of -38.1% and a 14.47% success rate on recommended stocks. Currently, the analyst consensus on SELLAS Life Sciences Group is a Moderate Buy with an average price target of $10.00, representing a 300.00% upside.

Jason Carr on TipRanks | November 15, 2022

SELLAS Craters After Postponing Cancer Drug Milestone

Shares of SELLAS Life Sciences Group (NASDAQ: SLS) were in a downward spiral on Monday morning as the late-stage clinical biopharmaceutical company announced a business update. SELLAS announced that it was postponing the interim analysis of its Phase 3 registrational clinical trial for its lead asset galinpepimut-S (GPS) to late next year or early 2024 from its earlier timeline of early next year. GPS is the company's novel therapy used in the treatment of patients with acute myeloid leukemia (AML).

Shrilekha Pethe on TipRanks | November 14, 2022

Read More 'SLS' Stories Here

SLS Price Returns

1-mo -45.63%
3-mo -15.00%
6-mo -12.97%
1-year -57.21%
3-year -37.35%
5-year -99.37%
YTD -53.89%
2021 -4.82%
2020 35.12%
2019 -93.01%
2018 -84.23%
2017 -86.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7525 seconds.